166 related articles for article (PubMed ID: 10495037)
1. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.
Barbanti P; Fabbrini G; Ricci A; Cerbo R; Bronzetti E; Caronti B; Calderaro C; Felici L; Stocchi F; Meco G; Amenta F; Lenzi GL
Mov Disord; 1999 Sep; 14(5):764-71. PubMed ID: 10495037
[TBL] [Abstract][Full Text] [Related]
2. Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease.
Barbanti P; Fabbrini G; Ricci A; Bruno G; Cerbo R; Bronzetti E; Amenta F; Luigi Lenzi G
Mech Ageing Dev; 2000 Dec; 120(1-3):65-75. PubMed ID: 11087905
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study.
Amenta F; Bronzetti E; Felici L; Ricci A; Tayebati SK
J Auton Pharmacol; 1999 Jun; 19(3):151-9. PubMed ID: 10511471
[TBL] [Abstract][Full Text] [Related]
4. Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with [3H]7-OH-DPAT: a combined radioligand binding assay and immunochemical study.
Ricci A; Bronzetti E; Felici L; Greco S; Amenta F
J Neuroimmunol; 1998 Dec; 92(1-2):191-5. PubMed ID: 9916894
[TBL] [Abstract][Full Text] [Related]
5. Age-dependent changes in the expression of dopamine receptor subtypes in human peripheral blood lymphocytes.
Barili P; Bronzetti E; Felici L; Ferrante F; Ricci A; Zaccheo D; Amenta F
J Neuroimmunol; 1996 Dec; 71(1-2):45-50. PubMed ID: 8982102
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D3 receptor in peripheral mononuclear cells of essential hypertensives.
Ricci A; Bronzetti E; Mulatero P; Schena M; Veglio F; Amenta F
Hypertension; 1997 Dec; 30(6):1566-71. PubMed ID: 9403584
[TBL] [Abstract][Full Text] [Related]
7. Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine?
Barbanti P; Bronzetti E; Ricci A; Cerbo R; Fabbrini G; Buzzi MG; Amenta F; Lenzi GL
Neurosci Lett; 1996 Mar; 207(2):73-6. PubMed ID: 8731424
[TBL] [Abstract][Full Text] [Related]
8. Postnatal development of dopamine receptor expression in rat peripheral blood lymphocytes.
Tomassoni D; Bronzetti E; Cantalamessa F; Mignini F; Ricci A; Sabbatini M; Tayebati SK; Zaccheo D
Mech Ageing Dev; 2002 Mar; 123(5):491-8. PubMed ID: 11796134
[TBL] [Abstract][Full Text] [Related]
9. [3H]spiperone binding to lymphocyte in extrapyramidal disease and in aging.
Członkowska A; Jachowicz-Jeszka J; Członkowski A
Brain Behav Immun; 1987 Sep; 1(3):197-203. PubMed ID: 2975511
[TBL] [Abstract][Full Text] [Related]
10. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors.
Wood M; Dubois V; Scheller D; Gillard M
Br J Pharmacol; 2015 Feb; 172(4):1124-35. PubMed ID: 25339241
[TBL] [Abstract][Full Text] [Related]
11. Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7-OH-DPAT.
Ricci A; Veglio F; Amenta F
J Neuroimmunol; 1995 May; 58(2):139-44. PubMed ID: 7759603
[TBL] [Abstract][Full Text] [Related]
12. Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.
Bezard E; Gray D; Kozak R; Leoni M; Combs C; Duvvuri S
CNS Neurol Disord Drug Targets; 2024; 23(4):476-487. PubMed ID: 36999711
[TBL] [Abstract][Full Text] [Related]
13. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
Hurley MJ; Mash DC; Jenner P
Eur J Neurosci; 2003 Nov; 18(9):2668-72. PubMed ID: 14622169
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study.
Ricci A; Amenta F
J Neuroimmunol; 1994 Aug; 53(1):1-7. PubMed ID: 8051291
[TBL] [Abstract][Full Text] [Related]
15. A post-mortem study on striatal dopamine receptors in Parkinson's disease.
Rinne JO; Laihinen A; Lönnberg P; Marjamäki P; Rinne UK
Brain Res; 1991 Aug; 556(1):117-22. PubMed ID: 1834312
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes.
Tice MA; Hashemi T; Taylor LA; Duffy RA; McQuade RD
Pharmacol Biochem Behav; 1994 Nov; 49(3):567-71. PubMed ID: 7862709
[TBL] [Abstract][Full Text] [Related]
17. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance.
Maggio R; Aloisi G; Silvano E; Rossi M; Millan MJ
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S2-7. PubMed ID: 20123551
[TBL] [Abstract][Full Text] [Related]
18. [The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors].
Tadori Y; Kobayashi H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2014 Nov; 34(5-6):127-32. PubMed ID: 25536763
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
Fariello RG
Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
[TBL] [Abstract][Full Text] [Related]
20. Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes.
Barbanti P; Fabbrini G; Ricci A; Pascali MP; Bronzetti E; Amenta F; Lenzi GL; Cerbo R
Cephalalgia; 2000 Feb; 20(1):15-9. PubMed ID: 10817442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
